GNH USA

Europe — EMA

Nintedanib Olpha

GNH USA supplies Nintedanib Olpha (Nintedanib), a tyrosine kinase inhibitor for IPF, NSCLC (with docetaxel) and systemic sclerosis‑ILD. Quote for supply.

Nintedanib

Request sourcing

1
Pack/s

What is Nintedanib?

Nintedanib, the active ingredient in Nintedanib Olpha, is a tyrosine kinase inhibitor presented as an oral capsule for oral use. It treats idiopathic pulmonary fibrosis, non‑small cell lung cancer in combination with docetaxel, and systemic sclerosis‑associated interstitial lung disease.

GNH USA supplies Nintedanib Olpha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Nintedanib used for?

Nintedanib acts on fibrotic and oncogenic pathways and is indicated for several serious lung conditions.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Non‑small cell lung cancer (with docetaxel): improves progression‑free survival when used in combination therapy. Systemic sclerosis‑associated interstitial lung disease: reduces the rate of forced vital capacity decline.

What are the side effects of Nintedanib?

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Decreased appetite - Weight loss - Abdominal pain

Serious or Rare Side Effects: - Elevated liver enzymes (hepatotoxicity) - Bleeding events, including gastrointestinal hemorrhage - Arterial thromboembolic events (e.g., myocardial infarction, stroke) - Severe infections - Gastrointestinal perforation - Severe skin reactions such as Stevens‑Johnson syndrome

What precautions apply to Nintedanib?

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline and periodic hepatic enzyme tests. Assess bleeding risk: avoid concomitant use of strong anticoagulants when possible. Evaluate cardiovascular status: watch for signs of arterial thrombosis. Pregnancy and lactation: safety unknown; avoid use in pregnant or nursing women. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

What does Nintedanib interact with?

Nintedanib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - P‑gp substrates (e.g., digoxin): monitor plasma levels. - NSAIDs: may augment bleeding tendency. - Antiplatelet agents (e.g., aspirin): observe for hemorrhagic complications.

Frequently asked questions

What conditions is Nintedanib Olpha used to treat?+
Nintedanib Olpha is prescribed for idiopathic pulmonary fibrosis, for non‑small cell lung cancer when given together with docetaxel, and for systemic sclerosis‑associated interstitial lung disease. In each case the drug aims to slow disease progression by targeting key growth‑factor pathways.
How does Nintedanib work at the molecular level?+
The molecule blocks several receptor tyrosine kinases—vascular endothelial growth factor receptors, platelet‑derived growth factor receptors and fibroblast growth factor receptors. By inhibiting these signals, it reduces fibroblast activation, new blood‑vessel formation and the deposition of scar tissue that characterise fibrotic and certain cancerous processes.
What is the usual dose of Nintedanib Olpha?+
The dosage regimen is individualized by the prescribing clinician based on the specific indication, patient characteristics and any concomitant therapies. Health‑care providers determine the appropriate strength, frequency and duration of treatment in accordance with approved labeling and clinical guidelines.
Is Nintedanib Olpha safe to use during pregnancy or while breastfeeding?+
Safety data for Nintedanib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Consequently, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the possible risk, and a physician’s assessment is required.
How do I order Nintedanib Olpha from GNH USA?+
To request Nintedanib Olpha, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.
How does Nintedanib compare with the main alternative drug for IPF?+
The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both drugs aim to slow lung‑function decline, Nintedanib targets a broader range of tyrosine‑kinase receptors, whereas pirfenidone’s mechanism involves modulation of cytokine production and oxidative stress. Choice between them depends on efficacy, tolerability, drug‑interaction profile and individual patient factors.
What are the recommended storage and handling conditions for Nintedanib Olpha?+
Store the product at room temperature below 25 °C, in its original packaging to protect it from moisture and light. Do not refrigerate or freeze the capsules. Keep them out of reach of children and discard any product that shows signs of damage or deterioration.
How is Nintedanib Olpha administered to patients?+
Nintedanib Olpha is taken orally, usually as whole capsules with food to lessen gastrointestinal upset. Patients should swallow the capsule whole with water and follow the dosing schedule prescribed by their health‑care professional. Consistency with meals and timing helps maintain stable drug levels.
What are the most serious risks associated with Nintedanib Olpha?+
The most critical adverse events include liver enzyme elevations that may signal hepatotoxicity, serious bleeding episodes, arterial thromboembolic events such as heart attack or stroke, and rare but severe gastrointestinal perforations. Prompt medical evaluation is required if any of these symptoms arise.
Who should not take Nintedanib Olpha?+
Patients with known hypersensitivity to nintedanib or any capsule excipients should avoid the drug. It is also contraindicated in individuals with active severe liver disease, uncontrolled bleeding disorders, recent major cardiovascular events, and in pregnant or breastfeeding women unless a specialist determines that benefits outweigh risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nintedanib
Route
Oral Use
Manufacturer
Olpha As
Origin
EU

Related products

Ofev 100 mg/1

Ofev 100 mg/1

Nintedanib · 100 mg

Ofev
CAPSULE
Boehringer Ingelheim Pharmaceuticals, Inc.
USA
Ofev 150 mg/1

Ofev 150 mg/1

Nintedanib · 150 mg

Ofev
CAPSULE
Boehringer Ingelheim Pharmaceuticals, Inc.
USA
Agarf

Agarf

Nintedanib

Norameda Uab
EU
Agarf

Agarf

Nintedanib

Norameda Uab
EU